Jiangsu Bioperfectus Technologies Co Ltd Class A 688399
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥79.70
- Day Range
- ¥79.47–80.57
- 52-Week Range
- ¥46.52–91.68
- Bid/Ask
- ¥80.36 / ¥80.46
- Market Cap
- ¥4.72 Bil
- Volume/Avg
- 860,094 / 506,626
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.98
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 684
- Website
- http://www.s-sbio.com
Comparables
Valuation
|
Metric
|
688399
|
300289
|
002030
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.56 |
Price/Book Value | 1.37 | 1.41 | 0.97 |
Price/Sales | 11.98 | 5.48 | 7.94 |
Price/Cash Flow | 679.36 | 22.72 | 13.72 |
Price/Earnings
688399
300289
002030
Financial Strength
|
Metric
|
688399
|
300289
|
002030
|
|---|---|---|---|
Quick Ratio | 5.79 | 12.83 | 2.15 |
Current Ratio | 6.10 | 14.16 | 4.15 |
Interest Coverage | −45.10 | −19.77 | −78.04 |
Quick Ratio
688399
300289
002030
Profitability
|
Metric
|
688399
|
300289
|
002030
|
|---|---|---|---|
Return on Assets (Normalized) | −8.31% | −0.43% | −5.89% |
Return on Equity (Normalized) | −9.66% | −0.48% | −7.30% |
Return on Invested Capital (Normalized) | −10.10% | −1.02% | −7.42% |
Return on Assets
688399
300289
002030
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bngzbhyhw | Jkwk | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ndcxmvkpm | Zgqcgcz | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mjfpcqrn | Phcbxt | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ltfkbrtjq | Qsppjrx | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Drlqyqkm | Cqyp | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Phrsfmfn | Xvwj | $28.1 Bil | |||
| Moderna Inc
MRNA
| Wxkwyqwn | Khs | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Znvfbkcdh | Pfbw | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tnmcxdjgr | Fftzqpb | $13.4 Bil | |||
| Incyte Corp
INCY
| Ywrbdhhrf | Zbcpmcd | $12.7 Bil |
United States